Trials / Completed
CompletedNCT00070096
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with metastatic germ cell tumors that are refractory to cisplatin.
Detailed description
OBJECTIVES: * Determine the efficacy of ixabepilone in patients with metastatic cisplatin-refractory germ cell tumors. * Determine the safety of this drug in these patients. OUTLINE: Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1.3-4 years.
Conditions
- Brain and Central Nervous System Tumors
- Extragonadal Germ Cell Tumor
- Ovarian Cancer
- Testicular Germ Cell Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ixabepilone |
Timeline
- Start date
- 2003-08-01
- Completion
- 2007-06-01
- First posted
- 2003-10-07
- Last updated
- 2013-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00070096. Inclusion in this directory is not an endorsement.